Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$55.79
-1.2%		$53.86
$44.12
▼
$78.48
$5.46B1.761.45 million shs904,060 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$546.12
-2.1%		$509.50
$374.17
▼
$560.25
$141.61B0.321.13 million shs803,262 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-1.24%-3.34%+6.37%+7.62%+5.30%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-2.12%+0.82%+12.64%+22.22%+37.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$55.79
-1.2%		$53.86
$44.12
▼
$78.48
$5.46B1.761.45 million shs904,060 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$546.12
-2.1%		$509.50
$374.17
▼
$560.25
$141.61B0.321.13 million shs803,262 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-1.24%-3.34%+6.37%+7.62%+5.30%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-2.12%+0.82%+12.64%+22.22%+37.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.61
Moderate Buy$68.0621.99% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.96
Moderate Buy$569.524.29% Upside

Current Analyst Ratings Breakdown

Latest VRTX and CRSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$665.00
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$653.00
8/31/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$80.00
8/31/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$82.00
8/25/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
8/25/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/25/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$80.00
8/6/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$55.00
8/5/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
8/5/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$560.00 ➝ $565.00
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$11M490.41N/AN/A$18.06 per share3.09
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.00B11.55$17.20 per share31.75$79.78 per share6.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.76N/AN/AN/A-3,368.72%-24.39%-18.25%11/9/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1831.7929.492.4235.00%23.09%16.72%11/2/2026 (Estimated)

Latest VRTX and CRSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.19-$0.94+$0.25-$0.94$7.45 million$10.18 million
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
6/30/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A-$0.94N/A-$0.94N/A$10.18 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.34
17.85
17.85
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46096.69 million91.67 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.80 million253.30 millionOptionable

Recent News About These Companies

AXQ Capital LP Buys New Holdings in Vertex Pharmaceuticals Incorporated $VRTX
September 5 at 3:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-axq-capital-lp-buys-new-holdings-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-05/
NEOS Investment Management LLC Purchases 19,219 Shares of Vertex Pharmaceuticals Incorporated $VRTX
September 4 at 5:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-neos-investment-management-llc-purchases-19219-shares-of-vertex-pharmaceuticals-incorporated-vrtx-2026-09-04/
Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 12-Month High - Here's What Happened
September 4 at 4:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003212
Nykredit A S Buys Shares of 248,068 Vertex Pharmaceuticals Incorporated $VRTX
September 3 at 5:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-buys-shares-of-248068-vertex-pharmaceuticals-incorporated-vrtx-2026-09-03/
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
September 2 at 12:30 PM  |  zacks.comhttps://www.zacks.com/stock/news/2983858/why-is-vertex-vrtx-up-14-4-since-last-earnings-report?cid=cs-stocknewsapi-ft-realtime_blog-2983858
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?
September 2 at 11:51 AM  |  barchart.comhttps://www.barchart.com/story/news/4404399/how-is-vertex-pharmaceuticals-stock-performance-compared-to-other-biotech-stocks
Vertex Pharmaceuticals (NASDAQ:VRTX) Hits New 52-Week High - Should You Buy?
September 2 at 10:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vertex-pharmaceuticals-nasdaq-vrtx-hits-new-52-week-high-should-you-buy-2026-09-02/
Proficio Capital Partners LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX
September 2 at 5:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-proficio-capital-partners-llc-takes-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-02/
Independence Bank of Kentucky Raises Position in Vertex Pharmaceuticals Incorporated $VRTX
September 2 at 4:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-independence-bank-of-kentucky-raises-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-02/
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks
September 2 at 1:22 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-vrtx-stock-trades-premium-010720573.html
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
September 1, 2026  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/35430/vertex-completes-10-billion-crinetics-acquisition-adding-rare-endocrine-growth-platform
Goldman Sachs refreshes conviction lists on both sides of the Atlantic
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/goldman-sachs-refreshes-conviction-lists-172632169.html
Vertex Pharmaceuticals names Jonathan Poole to CFO role
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/executive-leadership-and-management/vertex-pharmaceuticals-names-jonathan-poole-to-cfo-role/ar-AA2blk5q
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/oncoc4-appoints-dr-steve-chen-110000815.html
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-completes-acquisition-crinetics-pharmaceuticals-130300214.html
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Nwam LLC
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-bought-by-nwam-llc-2026-09-01/
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
August 31, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/1-p-500-stock-exciting-222040118.html
Strategic Advisors LLC Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-strategic-advisors-llc-decreases-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-31/
Quantitative Investment Management LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantitative-investment-management-llc-makes-new-investment-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-31/
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.53 Billion Stock Position in Vertex Pharmaceuticals Incorporated $VRTX
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-has-153-billion-stock-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-30/
Washington Trust Bank Sells 3,603 Shares of Vertex Pharmaceuticals Incorporated $VRTX
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-washington-trust-bank-sells-3603-shares-of-vertex-pharmaceuticals-incorporated-vrtx-2026-08-30/

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$55.79 -0.70 (-1.24%)
As of 09/4/2026 04:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$546.12 -11.84 (-2.12%)
As of 09/4/2026 04:00 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas